Filing Details

Accession Number:
0001209191-13-034478
Form Type:
4
Zero Holdings:
No
Publication Time:
2013-07-01 19:50:28
Reporting Period:
2013-07-01
Filing Date:
2013-07-01
Accepted Time:
2013-07-01 19:50:28
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
1401708 Nanostring Technologies Inc NSTG Biological Products, (No Disgnostic Substances) (2836) 200094687
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1431437 Clarus Ventures Ii, Llc C/o Of Clarus Ventures, Llc
101 Main Street, Suite 1210
Cambridge MA 02142
No No Yes No
1431439 Clarus Ventures Ii Gp, L.p. C/o Of Clarus Ventures, Llc
101 Main Street, Suite 1210
Cambridge MA 02142
No No Yes No
1431443 Clarus Lifesciences Ii, L.p. C/o Of Clarus Ventures, Llc
101 Main Street, Suite 1210
Cambridge MA 02142
No No Yes No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Acquisiton 2013-07-01 2,249,053 $0.00 2,249,053 No 4 C Direct
Common Stock Acquisiton 2013-07-01 812,045 $0.00 3,061,098 No 4 C Direct
Common Stock Acquisiton 2013-07-01 148,342 $0.00 3,209,440 No 4 C Direct
Common Stock Acquisiton 2013-07-01 750,000 $10.00 3,959,440 No 4 P Direct
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 C Direct
No 4 C Direct
No 4 C Direct
No 4 P Direct
Reported Derivative Transactions
Sec. Name Sec. Type Acquisiton - Disposition Date Amount Price Amount - 2 Price - 2
Common Stock Series C Preferred Stock Disposition 2013-07-01 2,249,053 $0.00 2,249,053 $0.00
Common Stock Series D Preferred Stock Disposition 2013-07-01 812,045 $0.00 812,045 $0.00
Common Stock Series E Preferred Stock Disposition 2013-07-01 148,342 $0.00 148,342 $0.00
Common Stock Serries D Preferred Warrant (Right to Buy) Disposition 2013-07-01 162,408 $8.45 162,408 $8.45
Common Stock Common Stock Warrant (Right to Buy) Acquisiton 2013-07-01 162,408 $8.45 162,408 $8.45
Remaning Holdings Exercise Date Expiration Date Equity Swap Involved Transaction Form Type Transaction Code Nature of Ownership
0 No 4 C Direct
0 No 4 C Direct
0 No 4 C Direct
0 2018-11-01 No 4 C Direct
162,408 2018-11-01 No 4 C Direct
Footnotes
  1. Clarus Ventures II GP, L.P. (the "GPLP"), as the sole general partner of Clarus Lifesciences II, L.P. ("Clarus"), may be deemed to beneficially own certain of the shares held of record by Clarus. The GPLP disclaims beneficial ownership of all shares held of record by Clarus in which the GPLP does not have an actual pecuniary interest. Clarus Ventures II, LLC (the "GPLLC"), as the sole general partner of the GPLP, may be deemed to beneficially own certain of the shares held of record by Clarus. The GPLLC disclaims beneficial ownership of all shares held of record by Clarus in which it does not have an actual pecuniary interest. Each of Nicholas Galakatos, a member of the board of directors, and Messrs. Henner, Liptak, Simon, Steinmetz and Wheeler, as individual Managing Directors of the GPLLC, may be deemed to beneficially own certain of the shares held of record by Clarus.
  2. Each of Messrs. Galakatos, Henner, Liptak, Simon, Steinmetz and Wheeler disclaims beneficial ownership of all shares held of record by Clarus in which he does not have an actual pecuniary interest.
  3. The Series C Preferred Stock, Series D Preferred Stock and Series E Preferred Stock converted into Common Stock on a one for one basis immediately prior to the completion of the Issuer's initial public offering of common stock and had no expiration date.
  4. The Series C Preferred Stock, Series D Preferred Stock and Series E Preferred Stock converted into Common Stock on a one for one basis immediately prior to the completion of the Issuer's initial public offering of common stock.